Journal of Clinical Investigation · 2024 · 32 citations · 24 references
MedicineNuclear MedicineOncologyDiagnostic RadiologyMetastasisTranslational OncologyMalignant NeoplasmsOncologic Nuclear ImagingPositron Emission TomographyProstate CancerProstate Cancer ImagingTumor ImagingLesion Uptake QuantificationMetastatic Tumor DetectionOncologic Pet ImagingPrimary Tumor CharacterizationProstate Cancer DiagnosisPsma-pet ImagingTumor Radiotracer ImagingTumor Uptake Kinetics
BACKGROUNDConsidering that trophoblast cell-surface antigen 2 (Trop2) is overexpressed in a wide range of human epithelial cancers, it presents an attractive target for diagnosis and treatment of multiple types of cancer. Herein, we have developed a Trop2-specific radiotracer, 68Ga-MY6349, and present a prospective, investigator-initiated trial to explore the clinical value of 68Ga-MY6349 PET/CT.METHODSIn this translational study, 90 patients with 15 types of cancer who underwent 68Ga-MY6349 PET/CT were enrolled prospectively. Among them, 78 patients underwent paired 68Ga-MY6349 and 18F-FDG PET/CT, and 12 patients with prostate cancer underwent paired 68Ga-MY6349 and 68Ga-PSMA-11 PET/CT.RESULTSAmong the 90 patients across 15 types of cancer, 68Ga-MY6349 uptake in tumors was generally high but heterogeneous, varying among lesions, patients, and cancer types. Trop2 expression level determined by immunohistochemistry was highly correlated with 68Ga-MY6349 uptake at primary and metastatic tumor sites. 68Ga-MY6349 PET/CT showed higher tumor uptake (quantified by maximum standardized uptake value) than 18F-FDG PET/CT in certain types of cancer, including breast (7.2 vs. 5.4, P < 0.001), prostate (9.2 vs. 3.0, P < 0.001), and thyroid cancers (8.5 vs. 3.7, P < 0.001). Compared with 68Ga-PSMA-11, 68Ga-MY6349 PET/CT exhibited comparable lesion uptake (12.2 vs. 12.5, P = 0.223) but a better tumor-to-background contrast (15.8 vs. 12.2, P < 0.001) for primary and metastatic prostate cancer, allowing visualization of more metastatic lesions.CONCLUSION68Ga-MY6349 PET/CT is a noninvasive method for comprehensively assessing Trop2 expression in tumors, which can improve diagnosis and staging for cancer patients and aid in decision making for Trop2-targeted therapies and advancing of personalized treatment.TRIAL REGISTRATIONClinicalTrials.gov NCT06188468.FUNDINGNational Natural Science Foundation of China, National Key R&D Program of China, Nuclear Energy R&D project, Fujian Research and Training Grants for Young and Middle-aged Leaders in Healthcare, Key Scientific Research Program for Young Scholars in Fujian, and Fujian Natural Science Foundation for Distinguished Young Scholars.
24
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2021 · 533 citations · Full text
Medicine, Oncology, Pharmacology +13
Hope S. Rugo, Aditya Bardia, Frederik Marmé et al. · The Lancet · 2023 · 427 citations · Full text
Medicine, Oncology, Pharmacology +17